Quetiapine for acute bipolar depression: A systematic review and meta-analysis

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 827-838

  Suttajit, Sirijit ^a   Srisurapanont, Manit ^a   Maneeton, Narong ^a   Maneeton, Benchalak ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Antipsychotic; Dropout; Efficacy; Remission; Response; Side effects

Indexed keywords

LITHIUM; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CHILD; COMBINATION CHEMOTHERAPY; CONSTIPATION; DISABILITY; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HUMAN; HYPOMANIA; INCREASED APPETITE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MANIA; META ANALYSIS; MONOTHERAPY; PROPHYLAXIS; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SEDATION; SLEEP QUALITY; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA; ACUTE DISEASE; BIPOLAR DISORDER;

ACUTE DISEASE; BIPOLAR DISORDER; HUMANS; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903385949     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S63779     Document Type: Article

References (37)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-552.
2. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry. 2000;61 Supp 13:S38-S41.
3. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68(2-3):167-181.
4. Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford: Oxford University Press; 1990.
5. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013;5:CD007815.
6. Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force On Treatment Guidelines For Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81-109.
7. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44.
8. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303-2312.
9. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-48.
10. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
11. Mayes TL, Bernstein IH, Haley CL, Kennard BD, Emslie GJ. Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents. J Child Adolesc Psychopharmacol. 2010;20(6):513-516.
12. Guy W, ed ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
13. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-171.
14. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
15. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
16. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. May 1989;28(2):193-213.
17. Sheehan DV. The Anxiety Disease. New York: Scribner's; 1983.
18. Higgins JPT Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated Mar 2011]. Oxford: The Cochrane Collaboration; 2011.
19. Boissel JP, Cucherat M, Li W, et al. [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]. Thérapie. 1999;54(4):405-411. French.
20. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21(11): 1575-1600.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
22. AstraZeneca [Webpage on Internet]. Effectiveness of Quetiapine XR versus Sertraline in acute depression as add-on therapy to previous mood stabilizer treatment: a pilot study. 2012. Available from: http://www.astrazenecaclinicaltrials.com/Submission/View?id=1406. Accessed September 17, 2013.
23. AstraZeneca [Webpage on Internet]. A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR) Tablets as Mono-Therapy or in Combination with Lithium in the Treatment of Patients with Acute Bipolar Depression. 2012. Available from: http://astrazenecagrouptrials.pharmacm.com/Submission/View?id=1405. Accessed September 17, 2013.
24. Calabrese JR, Keck PE, Jr., Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. July 2005;162(7):1351-1360.
25. McElroy SL, Weisler RH, Chang W, et al. EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-174.
26. Riesenberg RA, Baldytcheva I, Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Clin Ther. 2012;34(11):2202-2211.
27. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1-2):106-115.
28. Swartz HA, Frank E, Cheng Y. A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disord. 2012;14(2):211-216.
29. Thase ME, Macfadden W, Weisler RH, et al. BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609.
30. Young AH, McElroy SL, Bauer M, et al. EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150-162.
31. AstraZeneca [Webpage on Internet]. An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects with Bipolar Depression. 2011. Available from: http://www.astrazenecaclinicaltrials.com/Submission/View?id=1464. Accessed September 17, 2013.
32. DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11(5):483-493.
33. Bond A, Lader M. The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology. 1974;47(3):211-218.
34. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38.
35. Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14(1):27-35.
36. Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med. 2010;11(1):48-52.
37. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-1170.